글리메피리드

설포닐우레아계 항당뇨병제

경구용, 1일 1회 투여하는 항고혈당제입니다. 고양이의 인슐린 비의존성 당뇨병(NIDDM) 보조 치료에 유용할 수 있습니다. 고양이에서의 사용 경험은 매우 제한적입니다.

작용 기전: Glimepiride is a medium- to long-acting **secretagogue sulfonylurea**. **Primary Mechanism:** - Binds to the **SUR1 receptor** on the membrane of functioning pancreatic beta cells. - Closes ATP-sensitive potassium (K+) channels → cell depolarization. - Opens voltage-gated calcium (Ca2+) channels → calcium influx. - Triggers the exocytosis and **release of insulin** granules into the bloodstream. **Secondary Mechanism:** - With continued use, it may also increase peripheral tissue sensitivity to insulin, reducing insulin resistance.

동물 종별 용량

Cats

Treatment of NIDDM · 2 mg (total dose) per cat · PO · once daily
Treatment of NIDDM · 1-2 mg (total dose per cat) · PO · once daily

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

Hypersensitivity to glimepiride or other sulfonylureas
Diabetic ketoacidosis (DKA)

이상반응

Hypoglycemia
Dizziness
Asthenia
Liver function impairment (rare)
Allergic respiratory reactions (rare)
Dermatologic reactions (rare)
Hematologic reactions (rare)

약물 상호작용

Azole Antifungals (ketoconazole, itraconazole, fluconazole) · May increase plasma levels of glimepiride
Beta-Blockers · May potentiate hypoglycemic effect
Chloramphenicol · May displace glimepiride from plasma proteins
Corticosteroids · May reduce efficacy
Thiazide Diuretics · May reduce hypoglycemic efficacy
Isoniazid · May reduce hypoglycemic efficacy
Niacin · May reduce hypoglycemic efficacy
Phenothiazines · May reduce hypoglycemic efficacy
Phenytoin · May reduce hypoglycemic efficacy
Sulfonamides · May displace glimepiride from plasma proteins
Sympathomimetic Agents · May reduce hypoglycemic efficacy
Warfarin · May displace glimepiride from plasma proteins

모니터링

Fasting blood glucose
Appetite and attitude
Body condition
PU/PD resolution
Serum fructosamine
Glycosylated hemoglobin levels
Signs of hypoglycemia

과용량

Overdoses can lead to **hypoglycemia**, ranging from mild to severe and life-threatening. **Treatment:** - Immediate **glucose administration** (oral if conscious, IV dextrose if severe/unconscious). - **Intensive monitoring** is critical. - Due to the drug's long duration of activity, patients may require continuous glucose support (e.g., IV dextrose CRI) for **at least 48 hours** post-ingestion, even after apparent clinical recovery.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.